"which has me wondering how good an average of 2.4 could look"
This was my thought as well, after reading the announcement and all the testaments provided from the caregivers and the clinicians. The "very much improved" ratings..geez.
If anyone has ever personally seen a change of SVT to normal sinus rhythm after a dose of adenosine, or the change of the color of a liver after perfusion is established in liver transplant, this is sort of the instantaneous change that I can somehow relate to the improvements seen by NNZ2591 caregivers/clinicians from the participants. Not the speed of response per se, but the degree and enormity of change that it was able to produce.
In the intensive care, any small gains for the patients can make us happy. So to read this much response from a trial drug for a relatively short period of few weeks in relation to the patients' neurologic responses is flabbergasting, to say the least. I had goosebumps reading the reports earlier, but even then, I think we are just at the tip of it.
It blows my mind away thinking about the scale of what NNZ2591 can really do. I know that this might just sound like a biased take from the ecstacy that the results have just shown, but damn..
NEU Price at posting:
$22.20 Sentiment: Hold Disclosure: Held
(20min delay)